The evidence that IGF-1 triggers S100A7 up-regulation to drive the breast tumor microenvironment toward angiogenic programs suggests that we deepen our knowledge into the potential of the S100A7/RAGE pathway in breast cancer, particularly in those metabolic disorders characterized by enhanced activation of the IGF-1/IGF-1R pathway. This evidence concerns the gene S100A7 and breast carcinoma.